| Overview |
| bsm-30138M-FITC |
| human CD178/FITC |
| FCM |
| Human |
| Specifications |
| Unconjugated |
| Mouse |
| Monoclonal |
| 4A3 |
| IgG1/Kappa |
| n/a |
| Affinity purified by Protein G |
| 0.01M PBS, 0.5%BSA, 0.03% Proclin300 |
| Store at 2-8℃. Protect from light. Avoid freezing. |
| Target |
| 356 |
| P48023 |
| Tumor necrosis factor ligand superfamily member 6; FASLG; APO1L; Apoptosis (APO 1) antigen ligand 1; Fas-L; Apoptosis antigen ligand 1; APTL; CD178; CD-178; CD 178; CD95L; CD95 ligand; CD95-L; CD95L protein; FAS antigen ligand; Fas L; FASL; Fas ligand (TNF superfamily member 6); Generalized lymphoproliferative disease; TNF superfamily member 6; TNFSF6; TNFL6_HUMAN; Apoptosis antigen ligand; Tumor necrosis factor ligand superfamily member 6, membrane form; Tumor necrosis factor ligand superfamily member 6, soluble form; FASLG. |
| This gene is a member of the tumor necrosis factor superfamily. The primary function of the encoded transmembrane protein is the induction of apoptosis triggered by binding to FAS. The FAS/FASLG signaling pathway is essential for immune system regulation, including activation-induced cell death (AICD) of T cells and cytotoxic T lymphocyte induced cell death. It has also been implicated in the progression of several cancers. Defects in this gene may be related to some cases of systemic lupus erythematosus (SLE). Alternatively spliced transcript variants have been described. [provided by RefSeq, Nov 2014] |
| Application Dilution |
| FCM |
1:20-100 |
Powered by Bioz